Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether Spironolactone can improve the severity of
obstructive sleep apnea and improve cardiovascular biomarkers in people who are not regularly
using their Positive Airway Pressure (PAP) therapy.